Oliver Bechter

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Toward Minimal Residual Disease-Directed Therapy in Melanoma

Florian Rambow, Aljosja Rogiers, Oskar Marín-Béjar et al. · Cell · 2018 · 771 citations · Full text

Medicine, Dermatology, Oncology +12

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours

Bastian Kruse, Anthony Buzzai, Naveen Shridhar et al. · Nature · 2023 · 301 citations · Full text

Medicine, Cancer Biology, Immunology +14